However, from this data, which lacks longitudinal patient information, it is not possible to know if KSTAR predictions are accurately identifying the HER2-positive patients that will not be responsive to HER2-targeted therapies, a number that varies, but is thought to range between 35 and 50% of HER2-positive patients4,49, or instead demonstrates issues with inferring tumor activity from complex bulk biopsies. The gene discussed is ERBB2; the disease is neoplasm.